Drug data last refreshed 13h ago · AI intelligence enriched 1mo ago
Children's Claritin is an oral chewable tablet formulation of loratadine, a non-sedating second-generation antihistamine indicated for pediatric allergic rhinitis and urticaria. It works by selectively blocking H1-receptor sites, reducing histamine-mediated allergic symptoms in children.
Product is in late-stage lifecycle with moderate competitive pressure (30%), indicating a transitional commercial environment where brand defense and generic transition planning dominate team priorities.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Desloratadine,Phenylephrine Hcl,Ibuprofen Compared to Placebo in Treatment of Symptoms Associated With Common Cold/Flu
A Study to Learn What Participants Think of Treatment With Betamethasone Plus Loratadine to Treat Their Acute Allergic Rhinitis, Also Known as Hay Fever in Mexico
A Study to Evaluate Changes in Nasal Airflow of Loratadine/Pseudoephedrine Tablet and Fluticasone Propionate Nasal Spray in Subjects Following Allergen Exposure
A Study to Assess the Bioequivalence of Xisimin (Loratadine) Tablets Under Fasting and Fed Conditions in Healthy Participants Compared With Clarityne Tablets
A Study to Assess the Relative Bioavailability of Xisimin (Loratadine) Tablets Under Fasting and Fed Conditions in Healthy Participants Compared to Clarityne Tablets
Worked on CHILDREN'S CLARITIN at Bayer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on Children's Claritin offers limited growth opportunity given the zero linked job postings and LOE-approaching lifecycle stage. Roles available are primarily defensive—focused on market share retention, generic transition planning, and portfolio optimization rather than innovation or expansion.